ReviewAnalytical cellular pathology (Amsterdam)2017
Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials.
Review in Analytical cellular pathology (Amsterdam), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.European journal of medical research · 2025Review
- Combined Application of Human Amniotic Membrane Mesenchymal Stem Cells and a Modified PGS-co-PCL Film in an Experimental Model of Myocardial Ischemia-Reperfusion Injury.Applied biochemistry and biotechnology · 2023Article
- The Structural and the Functional Aspects of Intercellular Communication in iPSC-Cardiomyocytes.International journal of molecular sciences · 2022Review
- Mini review: Biomaterials in repair and regeneration of nerve in a volumetric muscle loss.Neuroscience letters · 2021Review
- Intramyocardial Bone Marrow Stem Cells in Patients Undergoing Cardiac Surgical Revascularization.The Annals of thoracic surgery · 2020Article
- Lack of a skeletal muscle phenotype in adult human bone marrow stromal cells following xenogeneic-free expansion.Stem cell research & therapy · 2020Article
- Cortical bone-derived stem cell therapy reduces apoptosis after myocardial infarction.American journal of physiology. Heart and circulatory physiology · 2019Article
- Current research trends and challenges in tissue engineering for mending broken hearts.Life sciences · 2019Review
- Chemical Engineering of Cell Therapy for Heart Diseases.Accounts of chemical research · 2019Review
- Potential clinical benefits of cell therapy in coronary heart disease: an update.Journal of thoracic disease · 2018Review
- Cigarette Smoking Impairs Adipose Stromal Cell Vasculogenic Activity and Abrogates Potency to Ameliorate Ischemia.Stem cells (Dayton, Ohio) · 2018Article
- Cardiac stem cell trials and the new world of cellular reprogramming: Time to move on.The Journal of thoracic and cardiovascular surgery · 2018Article
- Cardiac Progenitor Cells in Basic Biology and Regenerative Medicine.Stem cells international · 2018Review
- IGF-1-Overexpressing Mesenchymal Stem/Stromal Cells Promote Immunomodulatory and Proregenerative Effects in Chronic Experimental Chagas Disease.Stem cells international · 2018Article
- Thrombospondins: A Role in Cardiovascular Disease.International journal of molecular sciences · 2017Review
- Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials.Current cardiology reviews · 2017Review
- Stem cell therapy in critical limb ischemia: Current scenario and future trends.The Indian journal of radiology & imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because the human heart has limited potential for regeneration, the loss of cardiomyocytes during cardiac myopathy and ischaemic injury can result in heart failure and death. Stem cell therapy has emerged as a promising strategy for the treatment of dead myocardium, directly or indirectly, and seems to offer functional benefits to patients. The ideal candidate donor cell for myocardial reconstitution is a stem-like cell that can be easily obtained, has a robust proliferation capacity and a low risk of tumour formation and immune rejection, differentiates into functionally normal cardiomyocytes, and is suitable for minimally invasive clinical transplantation. The ultimate goal of cardiac repair is to regenerate functionally viable myocardium after myocardial infarction (MI) to prevent or heal heart failure. This review provides a comprehensive overview of treatment with stem-like cells in preclinical and clinical studies to assess the feasibility and efficacy of this novel therapeutic strategy in ischaemic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.